Table 2.
Neutralising antibody titers and outcome after challenge after DNA vaccination against RVFV
| Vaccine group | No. of animals | PRNT50 titersa | Challenge dose | Outcome after challenge with RVFV | ||
| Asymptomatic | Clinical signsb | Deathsc | ||||
| N | 4 | < 25 | 2.4 × 103 | 1 | 3 | |
| 4 | < 25 | 2.4 × 104 | 3 | 1 | ||
| GN/GC | 4 | 25 – 75 | 2.4 × 103 | 2 | 2 | |
| 4 | 25 – 75 | 2.4 × 104 | 3 | 1 | ||
| Ctrl/PUU-N | 4 | - | 2.4 × 103 | 3 | 1 | |
| 4 | - | 2.4 × 104 | 3 | 1 | ||
| Ctrl/pcDNA3.1 | 3 | - | 2.4 × 103 | 3 | ||
| 3 | - | 2.4 × 104 | 3 | |||
a Virus neutralising antibody titers after vaccination.
b Number of animals displaying clinical signs (ruffled fur/shivering), followed by complete recovery.
c Number of animals displaying a moribund condition (fatigue/"hunchback-like posture") followed by euthanization.